Claims

1. The use of (i) a naked binding member which binds to both SCR1 and SCR2 of CD55 or (ii) a nucleic acid encoding said binding member in the preparation of a medicament for the enhancement of complement deposition on a tissue, wherein the naked binding member is not bound to any agent having anti-tumour properties.

2. The use of (i) a naked binding member which binds to both SCR1 and SCR2 of CD55 or (ii) a nucleic acid encoding said binding member in the preparation of a medicament for treating cancer, wherein the naked binding member is not bound to any agent having anti-tumour properties.

3. The use according to claim 2 wherein the cancer is one or more of colorectal, breast , ovarian, cervical, gastric, lung, liver, skin and myeloid (e.g. bone marrow) cancer.

4. The use according to any one of the preceding claims wherein the binding member is an antibody or a fragment thereof.

5. The use according to any one of the preceding claims wherein the binding member binds to amino acids 83-93and SCR2 amino acids 101-112 and amino acids 145-157 of the

sequences shown in Figure 1b.

6. The use according to any one of the preceding claims wherein the binding member comprises one or more of the CDRs of the antibody, or a fragment thereof, produced by the cell line deposited at ATCC under accession number HB9173.

7. The use according to any one of the preceding claims wherein the binding member is the antibody 791T/36 produced by the hybridoma cell deposited at ATCC under accession number HB9173.

8. The use according to any one of claims 1 to 7 wherein the binding member comprises at least one human constant region.

9. A naked binding member which binds to both SCR1 and SCR2 for use in the treatment of cancer.

10. A naked binding member, which binds to both SCR1 and SCR2 of CD55, and an active agent as a combined preparation for simultaneous, separate or sequential use in the treatment of cancer, wherein said active agent is a chemotherapeutic agent, a pain relief agent or an anti-emetic.

11. The combined preparation according to claim 10, wherein said active agent is a Doxorubicin, taxol, 5-Fluorouracil, Irinotecan or Cisplatin.

12. The combined preparation according to claim 10 wherein said active agent is an antibody.

13. The combined preparation according to claim 13 wherein said active agent is an anti-CD20 antibody; an anti-VEGF antibody; an anti-CD171A antibody; an anti-CEA anti-idiotypic mAb; an anti-HMFG anti-idiotypic mAb; an anti-EGFR antibody, or an anti-HER2 antibody e.g. Herceptin, Genentech (South San Francisco, CA, USA).

14. The naked binding member according to any one of claims 9 to 10, or the combined preparation according to any one of claims 11 to 13 wherein the naked binding member is as defined in any one of claims 1 to 8.

15. A pharmaceutical composition for the treatment of cancer, wherein the composition comprises a naked binding member that binds to both SCR1 and SCR2 of CD55 and a pharmaceutically acceptable excipient, diluent or carrier.

16. The pharmaceutical composition according to claim 15, wherein the naked binding member

is as defined in any one of claims 1 to 8.

17. A method of neutralising the complement activation inhibition activity of CD55, comprising administration of a naked binding member which specifically binds to SCR1 and SCR2 of CD55.

18. A method of enhancing complement deposition comprising administration of a naked binding member which specifically binds to SCR1 and SCR2 of CD55.

19. A method of treating cancer comprising administration of a therapeutically effective amount of a naked binding member which specifically binds to SCR1 and SCR2 of CD55 to a mammal in need thereof.

20. A method according to any one of claims 17 to 19 wherein the naked binding member is as defined in any one of claims 1 to 8.